ORBi: Detailled Reference

Article (Scientific journals)

Soluble Biomarkers in Osteoarthritis – Current Status and Future Prospects?

Henrotin, Yves; Mobasheri, Ali

2012 • In European Musculoskeletal Review, 7 (4), p. 217-220

Peer reviewed

Permalink
https://hdl.handle.net/2268/132554

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

European Musculoskeletal Review henrotin (2).pdf

Publisher postprint (121.27 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] There is an acute need for reliable soluble biomarkers that can facilitate earlier diagnosis of osteoarthritis (OA), inform the prognosis and monitor and predict the responses of patients to therapeutic interventions. The number of biomarkers that have been validated and qualified is relatively small. This article summarises the current state of play in the field of OA soluble biomarkers. It discusses the barriers that prevent biomarkers from achieving their full potential and provides some perspectives for basic researchers and clinicians.

Disciplines :

Rheumatology

Author, co-author :

Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Mobasheri, Ali

Language :

English

Title :

Soluble Biomarkers in Osteoarthritis – Current Status and Future Prospects?

Publication date :

2012

Journal title :

European Musculoskeletal Review

ISSN :

1754-5072

eISSN :

1754-5080

Publisher :

Touch Briefings, London, United Kingdom

Volume :

7

Issue :

4

Pages :

217-220

Peer reviewed :

Peer reviewed

Available on ORBi :

since 19 October 2012

Statistics

Number of views

77 (8 by ULiège)

Number of downloads

3 (1 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

Bibliography

Dougados M, Structural progression is also driven by clinical symptoms in patients with osteoarthritis, Arthritis Rheum, 2004;50(5):1360-5
Berger MJ, Doherty TJ, Sarcopenia: prevalence, mechanisms, and functional consequences, Interdiscip Top Gerontol, 2010;37:94-114
Berenbaum F, Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype, Ann Rheum Dis, 2011;70(8):1354-6
Patra D, Sandell L, Evolving biomarkers in osteoarthritis?, J Knee Surg, 2011;24(4):241-9
Kraus VB, Burnett B, Coindreau J, et al., Application of biomarkers in the developement of drugs intended for the treatment of osteoarthritis, Osteoathritis Cart, 2011;19:515-42.
Biomarker Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Clin Pharmacol Therap, 2001;69:89-95
Bauer DC, Hunter DJ, Abramson SB, et al., Classification of osteoarthritis biomarkers: a proposed approach, Osteoarthritis Cart, 2006;14(8):723-7.
van Spil WE, DeGroot J, Lems WF, et al., Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria, Osteoarthritis Cart, 2010;18(5):605-12.
Patra D, Sandell L, Recent advances in biomarkers is osteoarthritis, Curr Opin Rheumatol, 2011;23:465-70
Mobasheri A, Henrotin Y, Biomarkers of Osteoarthritis: a review od recent research progress on soluble biochemical markers, published patents and areas for future development, Recent Patent on Biomarkers, 2011;1:28-43
Henrotin Y, Addison S, Kraus V, Deberg M, Type II collagen markers in osteoarthritis: what do they indicate?, Curr Opin Rheumatol, 2007;19(5):444-50
Deberg M, Labasse A, Christgau S, et al., New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis, Osteoarthritis Cart, 2005;13(3):258-65.
Deberg MA, Labasse AH, Collette J, et al., One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cart, 2005;13(12):1059-65.
Punzi L, Ramonda R, Deberg M et al., Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands, Osteoarthritis Cart, 2012;20(6):557-61.
Fernandez-Moreno M, Soto-Hermida A, Oreiro N et al., Mitochondrial haplogroups define two phenotypes of osteoarthritis, Frontiers in physiology, 2012;3:1-8.
Henrotin Y, Conrozier T, Deberg M, et al., Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1NO2) by hyaluronic acid intraarticular injections in patients with knee osteoarthritis, Ann Rheum Dis, 2011;70 (Suppl 3):214.
Henrotin Y, Kraus V, Brandt K, et al., Measurement of urinary Coll2-1NO2 is predictif of joint space narrowing in knee osteoarthritis, Osteoarthritis Cart, 2012;20 (Suppl 1):S80(149).
Robinson NE, Protein deamidation, Proc Natl Acad Sci USA, 2002;99(8):5283-8
Daumy GO, Wilder CL, Merenda JM, et al., Reduction of biological activity of murine recombinant interleukin-1 beta by selective deamidation at asparagine-149, FEBS Lett, 1991;278(1):98-102.
Catterall J, Hsueh M, Stabler T, et al., Protein modification by deamidation indicates variations in joint extracellular matrix turnover, J Biol Chem, 2012;287(7) 4640-51.
Gharbi M, Deberg M, Henrotin Y, Application for proteomic techniques in studying osteoarthritis: a review, Frontiers in Physiology, 2011;2:90-101
Williams A, Smith JR, Allaway D, ET AL., Applications of proteomics in cartilage biology and osteoarthritis research, Front Biosci, 2011;17:2622-44.
de Seny D, Sharif M, Fillet M, et al., Discovery and biochemical characterization of four novel biomarkers for osteoarthritis, Ann Rheum Dis, 2011;70(6):1144-52.
Fernandez-Puente P, Mateos J, Fernandez-Costa C, et al., identification of a panel of novel serum osteoarthritis biomarkers, J Proteome Res, 2011;10:5095-101.
Mateos J, Lourido L, Fernandez-Puente P, et al., Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF, J Proteomics, 2012;75:2069-78.
Henrotin Y, Gharbi M, Mazzucchelli G, et al., Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis, Arthritis Rheum, 2012;64(7):2260-7.
Van Spil WE, Jansen NWD, Bijlsma JWJ, et al., Clusters within a wide spectrum of biochemical markers of osteoarthritis: data from CHECK, a large cohort of individuals with early symptomatic osteoarthritis, Osteoarthritis Cart, 2012;20:745-54.
Tanishi N, Yamagiwa H, Hayami T, et al., Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation (urine CTX-II and NTX-I): the Matsudai Knee Osteoarthritis Survey, J Bone Miner Metab, 2009;27(5):605-12.
Di Cesare PE, Carlson CS, Stollerman ES, et al., Expression of cartilage oligomeric matrix protein by human synovium, FEBS Lett, 1997;412(1):249-52.
Ishii Y, Thomas AO, Guo XE, et al., Localization and distribution of cartilage oligomeric matrix protein in the rat intervertebral disc, Spine, 2006;31(14):1539-46.
Kong SY, Stabler TV, Criscione LG, et al., Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis, Arthritis Rheum, 2006;54(8):2496-504.
Andersson ML, Petersson IF, Karlsson KE, et al., Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis, Ann Rheum Dis, 2006;65(11):1490-4.

Similar publications